Characteristics of rheumatoid arthritis patients initiating therapy with abatacept, other biologics, and non-biologic disease-modifying anti-rheumatic drugs

被引：0
|
作者：
Hoffman, Veena [1 ]
Simon, Teresa A. [2 ]
Liu, Nan [3 ]
Lin, Nancy D. [3 ]
机构：
[1] Optum, Ann Arbor, MI USA
[2] Bristol Myers Squibb, Pennington, NJ USA
[3] Optum, Boston, MA USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2017年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
459
引用
收藏
页码：278 / 278
页数：1
相关论文
共 50 条
  • [41] Exploring the relationship between utilization patterns of biologic disease-modifying anti-rheumatic drugs and disease activity in rheumatoid arthritis patients
    Convertino, Irma
    Cazzato, Massimiliano
    Tillati, Silvia
    Giometto, Sabrina
    Gini, Rosa
    Valdiserra, Giulia
    Cappello, Emiliano
    Ferraro, Sara
    Bonaso, Marco
    Bartolini, Claudia C.
    Paoletti, Olga
    Lorenzoni, Valentina
    Filippi, Matteo
    Turchetti, Giuseppe
    Cristofano, Michele
    Blandizzi, Corrado
    Mosca, Marta
    Lucenteforte, Ersilia
    Tuccori, Marco
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 488 - 489
  • [42] Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
    Das, Priyam
    Weisenfeld, Dana
    Dahal, Kumar
    De, Debsurya
    Feathers, Vivi
    Coblyn, Jonathan S.
    Weinblatt, Michael E.
    Shadick, Nancy A.
    Cai, Tianxi
    Liao, Katherine P.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
  • [43] Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis
    Garrood, T
    Scott, DL
    [J]. BIODRUGS, 2001, 15 (08) : 543 - 561
  • [44] Combination Therapy with Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis
    Toby Garrood
    David L. Scott
    [J]. BioDrugs, 2001, 15 : 543 - 561
  • [45] Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
    Priyam Das
    Dana Weisenfeld
    Kumar Dahal
    Debsurya De
    Vivi Feathers
    Jonathan S. Coblyn
    Michael E. Weinblatt
    Nancy A. Shadick
    Tianxi Cai
    Katherine P. Liao
    [J]. Arthritis Research & Therapy, 25
  • [46] Perinatal use and discontinuation of disease-modifying anti-rheumatic drugs and biologics in women with rheumatoid arthritis: a cohort study
    Rebic, Nevena
    Sayre, Eric C.
    Zusman, Enav Z.
    Amiri, Neda
    Baldwin, Corisande
    De Vera, Mary A.
    [J]. RHEUMATOLOGY, 2020, 59 (07) : 1514 - 1521
  • [47] TREATMENT PATTERNS IN PSORIATIC ARTHRITIS (PSA) PATIENTS NEWLY INITIATED ON NON-BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS)
    Curtis, J.
    Gauthier, G.
    Hiscock, R.
    Zhang, F.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A517 - A517
  • [48] Lipid screening and statins alongside disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis
    Navarro-Millan, Iris
    Goyal, Parag
    Safford, Monika M.
    [J]. RHEUMATOLOGY, 2019, 58 (06) : 933 - 934
  • [49] Treatment Patterns of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
    Jin, Yinzhu
    Liu, Jun
    Desai, Rishi
    Kim, Seoyoung
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3476 - 3479
  • [50] Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs
    Pavelka, Karel
    Kavanaugh, Arthur F.
    Rubbert-Roth, Andrea
    Ferraccioli, Gianfranco
    [J]. RHEUMATOLOGY, 2012, 51 : V12 - V21
12345